Publication of a transparency notification received from Alychlo NV
28 April 2023 - 5:45PM
Publication of a transparency notification received from Alychlo NV
Liege, Belgium, 28 April 2023 – 17:45
CEST – Mithra (Euronext Brussels: MITRA), a company dedicated
to Women’s Health, today announces, in accordance with Article 14
of the Belgian Law of 2 May 2007 regarding the publication of major
shareholdings in issuers whose securities are admitted to trading
on a regulated market (the “Transparency Law”), that it received a
notification of transparency from Alychlo NV, with registered
offices at Lembergsesteenweg 19. 9820 Merelbeke, on 25, April
2023.
Alychlo NV notified Mithra that it has fallen
below the legal 5% threshold on 14 April 2023. Alychlo NV now holds
4.89% (2,791,923 shares) of the 57,073,622 shares currently
outstanding. Previously, Alychlo NV held 7.84% ( 4,144,730) of
Mithra’s outstanding securities.
The detailed transparency notifications are
available on the Investors section of Mithra
(mithra.com/en/investors/). An updated overview of the Mithra’s
shareholders structure will be included in the corporate governance
charter of Mithra, which will be made available on its website.
********
For more information, please contact:
Alexandra Deschner: +32 (0)4 349 28 22 –
investorrelations@mithra.com
About Mithra
Mithra (Euronext: MITRA) is a Belgian biotech
company dedicated to transforming Women’s Health by offering new
choices through innovation, with a particular focus on
contraception and menopause. Mithra’s goal is to develop products
offering better efficacy, safety and convenience, meeting women’s
needs throughout their life span. Mithra explores the potential of
the unique native estrogen estetrol in a wide range of applications
in women health and beyond. After having successfully launched the
first estetrol-based product in 2021, the contraceptive pill
Estelle®, Mithra is now focusing on its second product Donesta®,
the next-generation hormone therapy. Mithra also offers partners a
complete spectrum of solutions from early drug development,
clinical batches and commercial manufacturing of complex polymeric
products (vaginal ring, implants) and complex liquid injectables
and biologicals (vials, pre-filled syringes or cartridges) at its
technological platform Mithra CDMO. Active in more than 100
countries around the world, Mithra has an approximate headcount of
230 staff members and is headquartered in Liège, Belgium.
www.mithra.com
ESTELLE®, DONESTA® and MYRING® are registered
trademarks of Mithra Pharmaceuticals or one of its affiliates.
Important information
The contents of this announcement include
statements that are, or may be deemed to be, "forward-looking
statements". These forward-looking statements can be identified by
the use of forward-looking terminology, including the words
"believes", "estimates," "anticipates", "expects", "intends",
"may", "will", "plans", "continue", "ongoing", "potential",
"predict", "project", "target", "seek" or "should", and include
statements the Company makes concerning the intended results of its
strategy. By their nature, forward-looking statements involve risks
and uncertainties and readers are cautioned that any such
forward-looking statements are not guarantees of future
performance. The Company's actual results may differ materially
from those predicted by the forward-looking statements. The Company
undertakes no obligation to publicly update or revise
forward-looking statements, except as may be required by law.
- 2023-04-27_Mithra_Press-release_Transparency_Notification _EN-
FAST_FR version
Mithra Pharmaceuticals (EU:MITRA)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Mithra Pharmaceuticals (EU:MITRA)
Historical Stock Chart
Von Mai 2023 bis Mai 2024